What does HIV/AIDS cost? The answer to this question depends a lot on whom you ask.

Ask the UN and you’ll get the staggering sum of $10 billion. A year
. The annual per capita cost of treating infected Africans, where
much of the UN money goes, is around $1,100. One of the major
problems facing HIV/AIDS advocates is their inability to lower this
number. An estimated $600 is spent on anti-retroviral drugs, while
the remaining $500 is spent on other AIDS associated conditions.
Even $10 billion wouldn’t cover treatment for the more than 20
million Africans with HIV/AIDS. A considerable portion of the
proposed UN budget is directed not towards treatment but towards
prevention. A major problem is that no one can seem to agree on the
actual cost. Although the UN has held firm to their estimate, other
groups have presented vastly different figures. The World Health
Organization has presented four different scenarios which vary
wildly in both the projected outcome and cost. To merely maintain
the current status quo, WHO estimates more than $400 billion will
need to be spent over the next 20 years. To significantly reduce
annual new HIV infections, WHO’s figure is more than $700 billion.
Unfortunately such different figures can sometimes complicate
funding by making it hard for donors to decide how much to
give.

Ask someone who is living with HIV/AIDS and you’ll get a number
that’s a lot smaller. The average AIDS patient in America takes a
combination of drugs that add up to around $14,000 a year . Much of
this cost in the US is defrayed by private insurance, government
insurance or sometimes through AIDS drug assistance programs
(ADAPs) . These programs are meant to provide access to drugs for
low income individuals. Currently 89% of people enrolled in ADAPs
make less than 300% of the federal poverty level. However recently
the economic conditions have forced many states to scale back their
support of these programs. States have either closed enrollment
entirely, or narrowed eligibility-forcing people to drop out.
Currently the nationwide waiting list is at an all time high of
3,586 people .



Ask the companies that manufacture these lifesaving drugs and
you’ll be back to huge figures. One of the newest drugs to enter
the market, Fuzeon , is produced by the giant Swiss company, Roche.
Roche maintains that Fuzeon’s price (nearly $20,000 a year, or
three times the next most expensive drug) is due to the $600
million cost of development. The average drug begins to turn a
profit in 16 years, but analysts estimate that Fuzeon’s pricing,
and anticipated demand, could mean profits for Roche in as little
as three years.

Ask an economist and you’ll get a couple different figures. By 1995
more than $75 billion had been spent on AIDS. Since then, spending
has increased most years, with an average of $10 billion more being
spent every year. But money spent directly on AIDS does not even
begin to cover the true cost. In addition, economists have tried to
measure the costs related to lost productivity, wages, and
premature death, due to the disease. Figures vary, but some think
that indirect costs account for nearly 80 percent of the total cost
of AIDS. Worst case scenario guesses estimate that AIDS robs the
world of 1.4% of gross domestic product, or the equivalent of
wiping out the economy of Australia .



A government study in Uganda found that some companies are hiring
and training two employees for a single job in the hope that one
will stay healthy. The UN estimates that since 1981 AIDS has
reduced Africa’s overall labor force by 25%. Sick days and
absenteeism due to AIDS related illness have further reduced
productivity in the countries hit hardest by AIDS.

Ultimately the cost of HIV/AIDS is extraordinarily difficult to
measure. The disease affects so many people worldwide that it would
be impossible to assess the impact that it has had on everyone.
However it is obvious that unless something drastic changes, the
costs will continue to grow until they become unbearable.